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Objectives. This study was designed to assess the long-term
effects of a beta1-selective beta-adrenergic blocking agent on
mortality, in vivo hemodynamic function, left ventricular volume
and wall stress in post-myocardial infarction (MI) rats.
Background. Beta-blockers have shown beneficial results in
clinical studies after MI. However, the underlying mechanism is
not yet understood, and experimental studies have shown conflict-
ing results.
Methods. Bisoprolol (60 mg/kg body weight per day) was given
30 min or 14 days after MI or sham operation.
Results. The mortality rate was reduced only in early
bisoprolol-treated rats (29% vs. 46% in untreated rats, p < 0.05).
Heart rate was equally reduced in all treatment groups, and the
maximal rate of rise of left ventricular systolic pressure (dP/dtmax)
decreased in sham rats and in rats with a small to moderate
infarct size. Stroke volume index was unchanged in sham rats and
in rats with a small to moderate infarct with early or late
bisoprolol treatment and increased in rats with a large infarct in
the late bisoprolol group. Left ventricular volume was increased
by bisoprolol in sham rats and rats with a small infarct but not in
rats with a large infarct.
Conclusions. Treatments starting early (30 min) or late (14
days) after coronary artery ligation with bisoprolol increased left
ventricular volume in sham rats and in rats with a small infarct
but not in rats with a large infarct. Late bisoprolol treatment
improved stroke volume index, and early bisoprolol treatment
reduced diastolic wall stress, in rats with a large myocardial
infarct. Thus, bisoprolol effects on remodeling and cardiac per-
formance after myocardial infarction strongly depend on infarct
size and timing of treatment. This finding may explain previous
controversial results that did not consider infarct size and timing
of treatment.
(J Am Coll Cardiol 1998;31:692–700)
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Activation of neurohumoral systems may play an important
role in the development of progressive cardiac dysfunction
(1,2). Angiotensin-converting enzyme inhibitors have been
proven beneficial in the prevention of heart failure after
myocardial infarction (MI) both in animal models (3,4) and
clinical studies (5,6). The effect of short-term beta-adrenergic
blockage after MI was tested on, and a substantial reduction in
mortality from the use of oral propranolol was found (7). A
meta-analysis of ;29,000 patients (8) revealed a 13% reduc-
tion in mortality when intravenous beta-blockade was started
in the early hours of MI. Anti-ischemic or antiarrhythmic
effects of beta-blockers may be important in clinical studies.
However, the underlying mechanism is not yet completely
understood. Fishbein et al. (9) found that long-term propran-
olol treatment blunted myocardial hypertrophy and increased
left ventricular cavity dimensions in the rat model of experi-
mental MI. Oh et al. (10) reported similar observations in rats
exercising after MI and reperfusion. Hochman and Wong (11)
showed that atenolol had no significant effect on myocardial
infarct expansion in the rat model. In summary, these obser-
vations were in conflict with the beneficial effects of beta-
blockers reported in clinical studies. Various factors may have
influenced the experimental studies available so far: beta-
blocker type, degree of left ventricular dysfunction or size of
infarction and time to start of treatment after MI. In addition,
detailed hemodynamic studies have not been performed to
determine the long-term effect of beta-blockers after MI.
Therefore, the present study aimed to determine the effects of
early or late use of the beta-blocker bisoprolol on mortality,
hemodynamic function and left ventricular remodeling in rats
with infarcts of various sizes.
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Methods
Animals, experimental MI and pharmacologic interven-
tions. Adult male Wistar rats weighing 300 to 320 g were used.
Coronary artery ligation was performed as previously de-
scribed by Pfeffer et al. (3). In brief, rats were anesthetized by
ether, intubated and ventilated by a volume-constant rodent
ventilator (UB 7025 rodent ventilator, Hugo Sachs Elektronik,
Germany), and a left thoracotomy was performed. The heart
was exteriorized from the thorax, and the left main coronary
artery was ligated using a 5-0 Prolene suture between the
pulmonary artery outflow tract and left atrium. The heart was
then returned to its normal position and the thorax closed. All
procedures conformed to the guiding principles of the Amer-
ican Physiological Society and were approved by the institu-
tional animal research committee.
Dose-finding study. Dose-response curves of the effect of
bisoprolol on heart rate and mean arterial pressure (MAP)
were obtained. Rats were divided into four groups: group 1
(n 5 5) included untreated control rats; groups 2, 3 and 4 (n 5
5 for each group) were treated with bisoprolol (30, 60,
120 mg/kg body weight per day of drinking water, respectively)
for 1 week. On the day of study, rats were anesthetized with
ether, and polyethylene (PE50) catheters were inserted into
the right carotid artery and connected to a microtip manome-
ter (Millar) through a three-way stopcock for blood pressure
and heart rate measurements (Fig. 1). A dose of 60 mg/kg per
day was chosen for the main study on the basis of these
experiments.
Main study. Rats were housed in polyethylene cages (two
rats/cage) in climatized rooms with a 12-h light-dark cycle, fed
with standard laboratory food and had free access to water.
Rats were weighed, and their water consumption was mea-
sured at weekly intervals. Drug concentration in drinking water
was adjusted every week. Twelve groups of rats were studied:
the three treatment groups included untreated control rats;
early-B rats, in which bisoprolol (60 mg/kg per day) treatment
was started 30 min after coronary artery ligation, with the first
dose given per gavage followed by bisoprolol dissolved in
drinking water; and late-B rats, in which bisoprolol (60 mg/kg
per day) treatment was started 14 days after coronary artery
ligation. According to the extend of histologic infarct size, four
additional subgroups in each treatment group were estab-
lished. These included rats in which failure of ligation of the
coronary artery occurred (sham) or in which infarct size was
,30% (small), ranged from 30% to ,45% (moderate) or was
$45% (large).
Hemodynamic studies. Eight weeks after coronary ligation,
rats were reanesthetized with ether. Polyethylene cannulas
were inserted into the trachea for artificial ventilation and into
the right carotid artery and jugular vein for pressure measure-
ments. Pressures were measured through a short segment of a
fluid-filled PE50 tubing connected to a microtipped manome-
ter (Millar) through a three-way stopcock, with zero adjusted
to midchest level. The carotid cannula was briefly advanced
into the left ventricle and then withdrawn to the aortic arch
while pressure were recorded. The jugular vein cannula was
advanced to the right atrium. Left ventricular systolic and
Abbreviations and Acronyms
CI 5 cardiac index
CK 5 creatine kinase
dP/dtmax 5 maximal rate of rise of left
ventricular systolic pressure
MAP 5 mean arterial pressure
MI 5 myocardial infarction
RAP 5 right atrial pressure
SVI 5 systemic vascular index
TPRI 5 total peripheral resistance index
Figure 1. Dose–response curves for heart rate (A) and MAP (B) with
various doses of bisoprolol. Data shown are mean value 6 SEM. *p ,
0.05 versus bisoprolol, 0 mg/kg per day.
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end-diastolic pressures, the maximal rate of rise of left ventric-
ular systolic pressure (dP/dtmax), MAP, heart rate and mean
right atrial pressure (RAP) were measured under light ether
anesthesia and spontaneous respiration.
During positive pressure ventilation and after midsternal
thoracotomy, a calibrated flow probe (2.5 mm, Gould Statham
Instruments, Hato Rey, Puerto Rico) was placed around the
ascending aorta for continuous measurement of aortic blood
flow. Mean aortic blood flow was obtained electronically and
taken as the cardiac index (CI) (ml/min per kg body weight)
(3). Systemic vascular resistance index (SVRI) was calculated
as (MAP 2 RAP)/CI.
After a stable state was established, baseline measurements
were carried out over a 10-min period. Warmed (39 to 40°C)
Tyrode’s solution was then infused into a femoral vein at the
rate of 40 ml/kg per min for 45 s or until maximal flow was
achieved (12). This infusion produces an increase in cardiac
output to peak values, followed by a plateau, despite further
elevation of right atrial pressure. Maximal cardiac perfor-
mance was defined as peak values of cardiac index and stroke
volume index during this Tyrode’s infusion.
Ten to 15 min after the volume load, when all hemodynamic
variables had returned to baseline levels, the flow probe was
removed, and the arterial catheter was advanced into the left
ventricle. The ascending aorta was briefly occluded around
the catheter by a suture to produce contractions that are
isovolumetric except for coronary flow. Measurements were
made of left ventricular peak systolic and end-diastolic
pressures. Maximal left ventricular developed pressure was
calculated as peak systolic minus end-diastolic pressure
during aortic occlusion. These measurements defined the
maximal pressure-generating ability of the left ventricle, as
previously described (13).
Left ventricular volume. The passive pressure–volume
characteristics of the left ventricle were obtained as previously
described (14). The heart was arrested by potassium chloride
and a double-lumen catheter (PE 50 inside PE 200) was
inserted into the left ventricle through the ascending aorta.
The right ventricular free wall was incised to avoid fluid
accumulation. The atrioventricular groove was ligated, and
isotonic saline was infused at a rate of 0.76 ml/min through one
lumen while intraventricular pressure was continuously re-
corded through the other lumen from negative pressure to
30 mm Hg. At least three reproducible pressure–volume curves
were obtained within 10 min of cardiac arrest, well before the
onset of rigor mortis. Stiffness constants (K0, K1, K2, K3 and
K4) were defined as previously described by Fletcher et al. (13).
Ventricular volumes at pressures of 0, 2.5, 5, 10, 15, 20 and
30 mm Hg were calculated from the pressure–volume curve.
The operating left ventricular end-diastolic volume was de-
rived from the left ventricular pressure–volume curve (3) and
was defined as the volume on the pressure–volume curve
corresponding to a filling pressure equal to in vivo end-
diastolic pressure.
Infarct size. The method used to process the heart for the
measurement of infarct size was similar to that described by
Pfeffer et al. (3). After the pressure–volume data had been
recorded, the hearts were fixed in the distended form in 10%
buffered formalin for 24 h and then dissected into the left
ventricle plus interventricular septum and right ventricular free
wall, which were weighed separately. The whole left ventricle
was dehydrated in alcohol, cleared in xylene and embedded in
paraffin. Transverse serial sections of 10-mm thickness were
obtained in 1-mm intervals from apex to base and mounted
and stained according to the phosphotungstic acid hematoxylin
method in that necrotic infarct tissue stained red and nonin-
farcted myocardium blue. Ten to 12 sections were obtained
from each heart. The slices were projected, and the lengths of
infarct and total left ventricle on both epicardial and endocar-
dial surfaces of each section were measured using a calibrated
digitizer (Numonics Digitizer 2200). Infarct size was calculated
by dividing the sum of the planimetered endocardial and
epicardial circumferences of the infarcted area by the sum of
the total epicardial and endocardial circumferences of the left
ventricle.
Left ventricular shape. The method used for measurement
of left ventricular shape was previously described (14). Left
ventricular diameter was measured as the maximal distance
from the endocardial surface of the septum to the endocardial
surface of the free left ventricular wall, along with a line
perpendicular to the septum and, accordingly, was used as a
measure of aneurysmal shape distortion. Left ventricular free
wall thickness, which represents scar thickness in rats with
infarction, was measured at the point where the left ventricular
diameter reached the free left ventricular wall. Average septal
thickness was determined as the septal area enclosed by two
lines originating from the center of gravity of the endocardial
circumference that connected the two origins of right ventric-
ular free wall divided by the average of right and left ventric-
ular surface length. These measurements were performed by
using a calibrated digitizing tablet (Numonics Digitizer 2200).
Data analysis. Results are expressed as mean value 6
SEM. We used multiple comparisons to find differences be-
tween the various infarct and treatment groups; the compari-
sons were corrected by the Bonferroni test. Differences in
mortality among the various treatment groups were deter-
mined by chi-square and Fisher exact test; p , 0.05 was
considered to indicate statistical significance.
Results
A total of 289 rats underwent the surgical procedure: 89 in
the control group, 93 in the early-B group and 107 in the late-B
group. A total of 107 rats died before hemodynamic measure-
ments (102 rats died within 24 h after coronary ligation).
Differences were found in total mortality between the control
(46%) and early-B (29%) groups (p , 0.05). The mortality rate
was 34% in the late-B group (p 5 NS vs. control or early-B
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rats). Infarct size was similar among the various treatment
groups (Table 1).
Body weight and ventricular weights. Table 2 shows body
and heart weights for the various groups. Body weight was
somewhat lower in rats with a large infarct than in sham rats
and in bisoprolol-treated animals with a moderate infarct size
versus untreated rats. Left ventricular weight was reduced in
untreated rats with a large infarct versus sham rats but was not
significantly different from early-B or late-B group rats.
Hemodynamic measurements before thoracotomy. Table 3
shows hemodynamic variables obtained before thoracotomy.
Left ventricular systolic pressure and MAP as well as dP/dtmax
were in general reduced by bisoprolol, although this reduction
did not achieve statistical significance in each individual group.
Heart rate was consistently reduced by ;20% in all groups.
Large infarcts were characterized by lower arterial and higher
left ventricular end-diastolic pressures.
Hemodynamic measurements at baseline after thoracot-
omy. As shown in Table 4, CI was decreased by bisoprolol in
sham rats and in rats with a small infarct but not in rats with a
large infarct. Stroke volume index (SVI) was increased in this
group by late bisoprolol treatment. Total peripheral resistance
index (TPRI) was increased in rats with a large infarct in the
untreated group and in the early-B group. Both early and late
bisoprolol treatment significantly increased TPRI in sham but
not in infarcted rats.
Peak cardiac performance. These effects of bisoprolol
treatment in general persisted during volume loading (Table
5). Peak CI was reduced by early or late bisoprolol treatment
because of the reduced heart rate. Peak SVI was again
improved by late bisoprolol treatment in rats with a large
infarct. In contrast, peak developed pressure was even reduced
in this group by late bisoprolol treatment. In general, rats with
a large infarct had a reduced peak CI, SVI and developed
pressure but increased TPRI and left ventricular end-diastolic
pressure.
Table 1. Myocardial Infarct Size in Untreated and Treated Rats
Treatment
Sham
Operation
Infarct Size
Small
(,30%)
Moderate
($30% to ,45%)
Large
($45%)
Untreated
MI (%) 0 18 6 3 39 6 1 51 6 2
No. of rats 15 9 8 11
Early-B
MI (%) 0 17 6 2 38 6 1 50 6 2
No. of rats 16 11 14 8
Late-B
MI (%) 0 21 6 1 37 6 1 54 6 1
No. of rats 22 17 13 9
Data presented are mean value 6 SEM, unless otherwise indicated. Early-
B 5 early bisoprolol treatment; Late-B 5 late bisoprolol treatment; MI 5
myocardial infarction.
Table 2. Body and Heart Weights
Sham
Operation
Infarct Size
Small
(,30%)
Moderate
($30% to ,45%)
Large
($45%)
BW (g)
Untreated 522 6 10 510 6 16 552 6 14 467 6 15*
Early-B 508 6 17 519 6 13 490 6 12† 428 6 18*
Late-B 491 6 13 496 6 13 499 6 14 474 6 16
LVW (g)
Untreated 0.945 6 0.017 0.946 6 0.051 0.976 6 0.027 0.839 6 0.044*
Early-B 0.929 6 0.031 0.946 6 0.030 0.968 6 0.029 0.840 6 0.050
Late-B 0.909 6 0.025 0.936 6 0.028 0.898 6 0.016* 0.908 6 0.035
LVW/BW (g/kg)
Untreated 1.812 6 0.026 1.855 6 0.072 1.769 6 0.030 1.811 6 0.113
Early-B 1.827 6 0.021 1.828 6 0.055 1.980 6 0.054† 1.993 6 0.148
Late-B 1.862 6 0.038 1.890 6 0.042 1.813 6 0.051 1.927 6 0.081
RVW (g)
Untreated 0.262 6 0.014 0.267 6 0.019 0.291 6 0.024 0.297 6 0.028
Early-B 0.262 6 0.016 0.250 6 0.012 0.270 6 0.012 0.267 6 0.036
Late-B 0.247 6 0.008 0.234 6 0.012 0.260 6 0.012 0.276 6 0.021
RVW/BW (g/kg)
Untreated 0.501 6 0.026 0.520 6 0.027 0.530 6 0.049 0.647 6 0.071
Early-B 0.513 6 0.024 0.484 6 0.024 0.554 6 0.030 0.626 6 0.087
Late-B 0.508 6 0.017 0.473 6 0.024 0.522 6 0.020 0.599 6 0.069
*p , 0.05 versus sham-operated rats in same treatment group. †p , 0.05 versus untreated rats with comparable
infarct size. Data presented are mean value 6 SEM. BW 5 body weight; LVW 5 left ventricular weight; RVW 5 right
ventricular weight; other abbreviations as in Table 1.
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Left ventricular volume. The complete pressure–volume
curves of sham rats and rats infarcts of various sizes in the
untreated, early-B and late-B groups are shown in Figure 2. A
rightward shift of the pressure–volume curves was found with
increasing infarct size. Accordingly, histologic left ventricular
diameter and cavity (endocardial area) were increased (not
shown). Bisoprolol treatment tended to increase left ventricu-
lar volume in sham rats and in rats with a small and moderate
infarct (Fig. 2). In rats with a large MI, this effect was not
significant, and pressure–volume curves were similar, irrespec-
tive of treatment. Stiffness constants (Table 6, K0 to K4) were
consistently reduced by a large infarct. Most important, biso-
prolol reduced stiffness constants in rats with a small to
moderate infarct but not in those with a large infarct. Free wall
(scar) thickness decreased with increasing infarct size in the
control, early-B and late-B groups and was not affected by
bisoprolol treatment (not shown). Septal thickness tended to
be increased in control rats with a large infarction and was not
affected by bisoprolol treatment.
As shown in Table 7, left ventricular operating volume and
volume/weight ratio tended to be increased by bisoprolol
treatment in sham rats and rats with a small to moderate
infarct but not in rats with a large infarct.
Discussion
Mortality. The mortality rate was reduced by 22% in rats
with early treatment with bisoprolol versus untreated rats.
Similar findings were reported by Smith et al. (15) who used
the vasodilator/beta-blocker carvedilol. Late treatment could
not be expected to reduce mortality because most animals died
before late therapy was established. Clinical studies have
shown that beta-blockers may reduce post-MI mortality (16),
with emphasis on an effect most prominent during the first 24 h
(17). Opitz et al. (18) studied the arrhythmia pattern in this
model using continuous electrocardiographic recording by an
implanted telemetry system, and two active arrhythmogenic
periods were found from 0 to 0.5 h and 1.5 to 9 h after coronary
ligation. Most deaths in that study were arrhythmic. In the
present study, mortality was calculated beginning from 30 min
after coronary ligation. Most rats died within 24 h, and it is
conceivable, although not proven, that the reduction of ven-
tricular fibrillation by bisoprolol was responsible for its benefit
(19).
Importance of infarct size. A major result of the present
study was that the effect of bisoprolol strongly depended on
Table 3. Hemodynamic Variables Before Thoracotomy
Sham
Operation
Infarct Size
Small
(,30%)
Moderate
($30% to
,45%)
Large
($45%)
LVSP (mm Hg)
Untreated 133 6 2 135 6 3 131 6 4 127 6 3
Early-B 127 6 4 123 6 4 125 6 3 116 6 3
Late-B 124 6 3 124 6 3 121 6 2 119 6 4
MAP (mm Hg)
Untreated 107 6 2 109 6 2 107 6 4 107 6 2
Early-B 104 6 3 98 6 3† 103 6 3 97 6 2†
Late-B 100 6 2 105 6 2 101 6 2 97 6 4
dP/dtmax (3
1,000 mm Hg/s)
Untreated 16.8 6 1.0 13.5 6 0.7 16.5 6 1.8 8.5 6 1.0*
Early-B 8.5 6 2.6† 9.5 6 0.9† 8.5 6 0.6† 7.1 6 1.1
Late-B 9.3 6 0.4† 9.5 6 0.5† 8.7 6 0.4† 7.1 6 0.5*
LVEDP (mm Hg)
Untreated 3.5 6 0.9 3.6 6 0.4 9.0 6 4.0 22.2 6 4.0*
Early-B 5.5 6 0.7 6.5 6 1.4 10.8 6 2.9 13.8 6 2.9
Late-B 6.0 6 0.7 5.9 6 0.4† 8.7 6 1.6 19.5 6 1.7*
RAP (mm Hg)
Untreated 0.7 6 0.3 0.4 6 0.2 0.4 6 0.3 2.4 6 0.8
Early-B 0.9 6 0.3 0.9 6 0.5 0.6 6 0.3 1.4 6 0.8
Late-B 0.2 6 0.2‡ 0.1 6 0.1 0.7 6 0.3 1.7 6 0.7
HR (beats/min)
Untreated 387 6 11 392 6 12 406 6 11 386 6 14
Early-B 299 6 14† 318 6 11† 317 6 8† 322 6 9†
Late-B 312 6 7† 315 6 7† 323 6 8† 323 6 6†
*p , 0.05 versus sham-operated rats in same treatment group. †p , 0.05
versus untreated rats with comparable infarct size. ‡p , 0.05 versus rats with
early bisoprolol treatment and comparable infarct size. Data presented are mean
value 6 SEM. dP/dtmax 5 maximal rate of rise of left ventricular systolic
pressure; HR 5 heart rate; LVEDP 5 left ventricular end-diastolic pressure;
LVSP 5 left ventricular systolic pressure; MAP 5 mean arterial pressure;
RAP 5 right atrial pressure; other abbreviations as in Table 1.
Table 4. Baseline Cardiac Performance
Sham
Operation
Infarct Size
Small
(,30%)
Moderate
($30% to
,45%)
Large
($45%)
MAP (mm Hg)
Untreated 98 6 1 99 6 2 99 6 2 98 6 2
Early-B 95 6 2 91 6 2 96 6 2 91 6 1
Late-B 94 6 2 96 6 1 91 6 2 89 6 2†
HR (beats/min)
Untreated 419 6 8 416 6 13 413 6 11 401 6 16
Early-B 336 6 17† 328 6 15† 338 6 11† 329 6 7†
Late-B 319 6 5† 326 6 9† 320 6 8† 315 6 7†
CI (ml/min per kg)
Untreated 258 6 11 234 6 14 225 6 9 193 6 12*
Early-B 193 6 9† 183 6 15 193 6 12 151 6 19
Late-B 195 6 11† 212 6 19 193 6 18 211 6 26
SVI (ml/kg)
Untreated 0.62 6 0.03 0.56 6 0.03 0.55 6 0.03 0.49 6 0.03*
Early-B 0.58 6 0.03 0.56 6 0.05 0.57 6 0.04 0.45 6 0.05
Late-B 0.61 6 0.03 0.65 6 0.05 0.59 6 0.05 0.66 6 0.07
TPRI (mm Hg/ml
per min per kg)
Untreated 0.37 6 0.01 0.43 6 0.03 0.43 6 0.02* 0.50 6 0.03*
Early-B 0.50 6 0.03† 0.53 6 0.06 0.51 6 0.04 0.66 6 0.09
Late-B 0.49 6 0.02† 0.49 6 0.04 0.53 6 0.07 0.47 6 0.07
*p , 0.05 versus sham-operated rats in same treatment group. †p , 0.05
versus untreated rats with comparable infarct size. Data presented are mean
value 6 SEM. CI 5 cardiac index; SVI 5 stroke volume index; TPRI 5 total
peripheral resistance index; other abbreviations as in Tables 1 and 3.
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infarct size. Bisoprolol consistently reduced dP/dtmax in sham-
operated rats and in rats with a small or moderate infarct size
and reduced CI and increased TPRI in sham-operated rats
and in rats with a small infarct. Thus, blood pressure was
maintained at reduced cardiac output by peripheral vaso-
constriction. In contrast, bisoprolol did not reduce dP/dtmax
in rats with a large infarct. In addition, these animals, when
treated late with bisoprolol, showed a substantial increase in
stroke volume at rest and during volume loading and
preservation of CI, whereas peak developed pressure was
reduced. In this group, bisoprolol did not induce an increase
in TPRI.
A rightward shift by bisoprolol of the pressure–volume
curves occurred in sham-operated rats and in rats with a small
infarct. This observation was in accordance with previous
experimental studies (9,10) but was not significant in rats
with a moderate infarct size and was virtually absent in rats
with a large infarct. The “operating left ventricular volume”
calculated for in vivo end-diastolic pressure was 0.62 6 0.10
in untreated, 0.57 6 0.11 in early-treated and 0.69 6 0.08 in
late-treated rats with a large infarct (p 5 NS) (Table 7). Left
ventricular end-diastolic pressure tended to be increased,
whereas the volume/mass ratio was more than doubled by
early or late beta-blockade in rats with a small infarct. In
contrast, left ventricular end-diastolic pressure tended to be
decreased after beta-blockade in animals with a large in-
farct, and the volume/mass ratio remained unchanged.
These data strongly suggest that diastolic wall stress was
increased in sham-operated rats and in rats with a small
infarct but was reduced by early beta-blockade in rats with a
large infarct. Finally, left ventricular stiffness was consis-
tently reduced by bisoprolol only in sham-operated rats
and in rats with a small or moderate infarct. However, there
was no significant effect of bisoprolol in rats with a large
infarct. In the rat model, quantitative micromorphologic
analysis demonstrated that propranolol could increase left
ventricular cavity (9,10). However, those studies tested
beta-blockers only in rats with an infarct size ,30% of the
left ventricle and therefore do not contradict the present
results.
Reduction of wall stress may explain the hemodynamic
effects in rats with a large infarct. Although individual variables
contributing to wall stress (volume, pressure, mass) were not
significantly changed by bisoprolol, their changes were com-
bined in favor of reduced wall stress. In addition, reduction of
heart rate and, thus, of “minute wall stress” by beta-blockade
may have contributed to improve myocardial energy balance in
rats with a large infarct. A previous study (20) used papillary
muscles isolated from rat heart 21 days after a large
myocardial infarction. These morphologically intact but
hypertrophied papillary muscles showed reduced developed
tension, impaired beta-adrenoceptor density and reduced
adenylate cyclase activity after beta-receptor stimulation,
respectively. Long-term propranolol treatment improved
developed tension and increased beta-adrenoceptor density
but did not improve adenylate cyclase activity or
isoproterenol-stimulated muscle function. Thus, the effect
of long-term beta-blockade on myocardial function ap-
peared unrelated to the beta-receptor–adenylate cyclase
system. The improvement in myocardial function was also
unrelated to hypertrophy because the cross-sectional area of
papillary muscle that was increased after MI was unchanged
by propranolol (20). Recently, Laser et al. (21) showed that
bisoprolol therapy preserved total creatine kinase (CK)
activity and prevented the shift of CK isoenzyme toward the
B isoenzymes and depletion of mitochondrial CK and
creatine. The increase in anaerobic lactic dehydrogenase
isoenzymes observed in untreated infarcted rats did not
occur during bisoprolol treatment. Thus, beta-blockade
prevented in part the changes in CK and lactate dehydro-
genase that are typical for myocardial hypertrophy and
failure (22).
Most post-MI changes depend on infarct size (23,24), and
the effect of angiotensin-converting enzyme inhibitors was also
Table 5. Peak Cardiac Performance
Sham
Operation
Infarct Size
Small
(,30%)
Moderate
($30% to
,45%)
Large
($45%)
MAPmax (mm Hg)
Untreated 93 6 3 89 6 4 85 6 3 85 6 3
Early-B 82 6 3† 76 6 4 78 6 3 76 6 4
Late-B 78 6 2† 84 6 3 74 6 3† 74 6 4
HRmax (beats/min)
Untreated 404 6 9 390 6 15 389 6 12 385 6 13
Early-B 317 6 7† 320 6 14† 329 6 10† 313 6 10†
Late-B 312 6 5† 313 6 7† 316 6 7† 297 6 10†
CImax (ml/min per kg)
Untreated 446 6 15 363 6 29* 307 6 25* 271 6 17*
Early-B 323 6 15† 278 6 23 289 6 19 241 6 26*
Late-B 329 6 12† 324 6 20 305 6 25 265 6 23*
SVImax (ml/kg)
Untreated 1.11 6 0.03 0.94 6 0.07 0.80 6 0.08* 0.71 6 0.04*
Early-B 1.02 6 0.05 0.86 6 0.05 0.88 6 0.05 0.77 6 0.08*
Late-B 1.06 6 0.04 1.03 6 0.06 0.97 6 0.08 0.89 6 0.07
TPRImax (mm Hg/ml
per min per kg)
Untreated 0.20 6 0.01 0.24 6 0.03 0.26 6 0.01* 0.28 6 0.02*
Early-B 0.24 6 0.01 0.26 6 0.02 0.26 6 0.02 0.31 6 0.04
Late-B 0.21 6 0.01 0.24 6 0.02 0.24 6 0.03 0.26 6 0.03
Dev Pmax (mm Hg)
Untreated 226 6 6 209 6 10 187 6 8* 163 6 6*
Early-B 221 6 4 182 6 10* 166 6 6* 150 6 6*
Late-B 201 6 5†‡ 190 6 3 174 6 5* 142 6 4*†
LVEDPmax (mm Hg)
Untreated 20.8 6 0.8 17.5 6 1.6 20.9 6 1.3 26.5 6 3.2
Early-B 20.1 6 0.8 19.8 6 1.7 22.9 6 1.6 24.5 6 2.4
Late-B 20.0 6 0.9 20.5 6 0.9 21.1 6 0.7 26.4 6 1.5*
*p , 0.05 versus sham-operated rats in same treatment group. †p , 0.05
versus untreated rats with comparable infarct size. ‡p , 0.05 versus rats with
early bisoprolol treatment and comparable infarct size. Data presented are mean
value 6 SEM. max 5 maximal; Dev P 5 developed pressure; other abbreviations
as in Tables 1, 3 and 4.
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found to be related to infarct size (3). The observation of the
present study that rats with a large infarct responded better to
beta-blockade than those with a small infarct is in good
accordance with clinical observations that showed that
post-MI patients with the highest risk and most severe
dysfunction benefited from beta-blocker therapy (2). In
addition, numerous studies (2) in patients with severe
chronic heart failure have documented that long-term beta-
blocker treatment may improve cardiac index and left
ventricular ejection fraction and may reduce cardiac filling
pressure. It is conceivable that neurohumoral systems are
most activated in these animals and patients (25–27) but not
in rats with a small infarct (28). Activation of the sympa-
Figure 2. Passive pressure–volume curves in sham-operated rats (A)
and in rats with a small (B), moderate (C) or large MI (D) in the
untreated (open circle), early bisoprolol (Early-B) treatment (open
squares) and late bisoprolol (Late-B) treatment (solid circles) groups.
Data shown are mean value 6 SEM. *p , 0.05 versus untreated rats
with a comparable infarct size.
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thoadrenal system might be a prerequisite for certain effects
of beta-blockade.
Early versus late treatment. Only late treatment improved
SVI at baseline and during volume loading in rats with a large
infarct, whereas early treatment had no consistent effect.
Operating left ventricular volume was not different between
sham-operated rats or rats treated by bisoprolol early or late;
therefore, the effect could not be explained by different left
ventricular geometry or afterload. Left ventricular end-
diastolic pressure tended to be lower, and an increased preload
and recruitment of the Frank-Starling reserve could be respon-
sible. However, mortality was different between the early and
late treatment groups, creating some selection bias. In addi-
tion, differences were small, and biologic relevance must be
questioned.
We thank Martin Finzel and Detlef Seufert for skillful technical assistance.
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